Lv5
1210 积分 2025-07-24 加入
Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma
4天前
已完结
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
1个月前
已完结
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
4个月前
已完结
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies
5个月前
已完结
A coiled-coil masking domain for selective activation of therapeutic antibodies
5个月前
已完结
A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma
6个月前
已完结
European Myeloma Network Consensus Statement on Functional High-Risk Multiple Myeloma
7个月前
已完结
皖公网安备34019202002308
